A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

When LVEF is >45% and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is <10%, continue treatment with ENHERTU ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Q3 2024 Earnings Call Transcript November 13, 2024 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

Around 10% of patients treated with Enhertu developed ILD or pneumonitis, compared to less than 2% of the Kadcyla group, although most of the cases were grade 1 and 2 and none were severe or life ...

starting November 10?just in time for the holiday season. This... at 08:05 ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product Daiichi Sankyo (TSE:4568) and ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best ... The company's marketed products include Tagrisso, Imfinzi ...